Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenoty...(tudy more than 3000 patients weretested ...),Health

Date:11/5/2007

tudy, more than 3,000 patients were tested for Haptoglobin phenotype, and 984 of these who had the Hp2-2 phenotype were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Primary endpoints of the study were non-fatal myocardial infarction (MI--heart attack), stroke and cardiovascular death. Results demonstrated a greater than 50% decrease in cardiovascular events in patients receiving Vitamin E (1.0 percent compared to 3.8 percent, p=0.004), leading to early termination of the study. Investigators determined this result to be predominantly due to a significant decrease in non-fatal myocardial infarction in the Vitamin E group.

"Our research group has postulated that the profoundly increased risk of, MI, stroke and cardiovascular death observed in DM patients with Hp2-2, established in many observational studies of more than 20,000 patients in recent years, may be a consequence of a defect in the antioxidant protection of Hp2-2," added Dr. Levy. "As a member of my group, Dr. Rabea Asleh, reported earlier today, this defect may interfere with reverse cholesterol transport. This in turn may promote a more inflamed and labile atherosclerotic plaque. It is gratifying to have had this opportunity to collaborate with Clalit Health Services, the largest health plan in Israel, in a large prospective clinical trial that provides strong support for the claim that Vitamin E can be targeted to DM patients with Hp2-2 and provide a significant clinical benefit."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metaboliz
'/>"/>

SOURCE Synvista Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)